OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Jennifer Pritzker Sells 22,500 Shares

Key Points

• Major shareholder Jennifer Pritzker sold 22,500 OrthoPediatrics shares at an average price of $23.35, generating $525,375. Following the transaction, she retained 6.5 million shares valued at roughly $151.9 million.
• OrthoPediatrics reported quarterly revenue of $70.51 million and an adjusted loss of $0.26 per share, beating analyst estimates for both metrics. Analysts project a full-year loss of $1.14 per share.
• KIDS shares recently traded at $22.41, while Wall Street maintained a “Moderate Buy” consensus with an average price target of $26.44; institutional investors own 69.05% of the company.

OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) major shareholder Jennifer Pritzker sold 22,500 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $23.35, for a total value of $525,375.00. Following the sale, the insider owned 6,504,133 shares of the company's stock, valued at approximately $151,871,505.55. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

OrthoPediatrics Price Performance

KIDS traded down $0.18 on Friday, hitting $22.41. 129,506 shares of the stock were exchanged, compared to its average volume of 173,525. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The firm has a market capitalization of $585.13 million, a price-to-earnings ratio of -13.34 and a beta of 0.99. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The business has a 50-day moving average of $21.74 and a two-hundred day moving average of $18.84.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Institutional Trading of OrthoPediatrics

A number of large investors have recently modified their holdings of KIDS. AIGH Capital Management LLC purchased a new position in OrthoPediatrics in the 2nd quarter worth approximately $5,161,000. Wasatch Advisors LP increased its stake in OrthoPediatrics by 56.6% in the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company's stock valued at $9,865,000 after acquiring an additional 186,357 shares during the last quarter. Roubaix Capital LLC raised its position in OrthoPediatrics by 23.8% during the first quarter. Roubaix Capital LLC now owns 290,047 shares of the company's stock valued at $4,603,000 after purchasing an additional 55,724 shares in the last quarter. Granahan Investment Management LLC lifted its stake in OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company's stock worth $14,231,000 after purchasing an additional 232,760 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new stake in OrthoPediatrics during the second quarter worth about $4,537,000. Institutional investors own 69.05% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on KIDS shares. Weiss Ratings raised shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 5th. Needham & Company LLC lifted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. BTIG Research increased their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a report on Wednesday, August 5th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source